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Abstract:  
Objectives: To determine the potential for dose escalation to a biological equivalent dose 
BED10≅100Gy in hypofractionated radiotherapy for locally advanced pancreatic cancer (LAPC). 
Materials and Methods: Ten unselected LAPC patients were retrospectively included in the study. 
Two fractionation regimens were compared (5 and 15 fractions). The aim was to cover 95% of the 
Planning Target Volume (PTV) with a BED10=54Gy (base dose=33Gy in 5 fractions, 42.5Gy in 15 
fractions) whilst respecting organs-at-risk (OAR) constraints. Once the highest PTV coverage was 
achieved dose escalation to a BED10≅100Gy (escalated dose=50Gy in 5 fractions, 67.5Gy in 15 
fractions) was attempted, limiting the PTV maximum dose to 130% of the escalated dose.  
Results: In 5 fractions, 95% PTV coverage by both base and escalated doses could be achieved for 
one patient with PTV more than 1cm away from OAR. 95% and 90% PTV coverage by the base dose 
was achieved in one and two patients respectively. In all other patients, coverage even by the base 
dose had to be compromised to comply with OAR constraints. In 15 fractions, 95% PTV coverage by 
the base dose was feasible for all patients except one. Dose escalation allowed improvement in target 
coverage by the base dose in both fractionation regimen whilst covering a sub-volume of the PTV 
with a BED10≅100Gy. Both fractionation schemes were equivalent in terms of dose escalation 
potential. 
Conclusion: LAPC patients with OAR close to the PTV are generally not eligible for 
hypofractionation with dose escalation. However, this planning study shows that it is possible to cover 
PTV sub-volumes with a BED10≅100Gy in addition to delivering a BED10=54Gy to 90-95% of the 
PTV as commonly prescribed to this population. Combined with an adaptive approach, this may 
maximize PTV coverage by a high BED on days with favourable anatomy. 
 
Keywords: pancreatic cancer, SBRT, hypofractionation, dose escalation, treatment planning  
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1. Introduction  
In 2017, pancreatic cancer was predicted to be the 3rd most common cause of cancer death in the 
United States (US) with a 5 year survival rate of only 8%[1]. At diagnosis, 30% of patients present 
with locally advanced, unresectable disease [2].  
Worldwide, the optimal treatment for locally advanced pancreatic cancer (LAPC) is controversial 
with conflicting results from phase 3 clinical trials on the survival benefit of standard fractionation 
chemoradiation (CRT) compared to chemotherapy alone [3–6].  
In recent years, hypofractionation and stereotactic body radiotherapy (SBRT) have been increasingly 
investigated for the treatment of LAPC. Characterized by high dose per fraction and highly conformal 
dosimetry, these offer the convenience of shorter overall treatment time, reduced time off full dose 
systemic therapy and potentially, improved local control. Yet, the close proximity of radiosensitive 
organs at risk (OAR) has led to so-called ‘low dose’ SBRT becoming a favoured approach [7]. Low 
rates of toxicity with a 1 year local control of 78% have been reported for dose regimens such as 
33Gy in 5 fractions [8]. This corresponds to a biological equivalent dose (BED10) of 54.8Gy, slightly 
lower than conventional regimens delivering a BED10 of 60-64Gy [4,9]. 
Although there have been no randomized control trials comparing CRT to SBRT, a systematic review 
of 19 trials suggests a median survival of 17 months with acceptable toxicity when using an SBRT 
approach [10]. This advantage is supported by a cancer database review from the US suggesting an 
improvement in overall survival in patients undergoing SBRT compared to other types of 
radiotherapy [11]. It should be noted that within these studies, heterogeneity of treatment regimens 
was significant. 
In an attempt to optimise the use of radiotherapy in LAPC, recent interest has focussed on the role of 
dose escalated treatments. A retrospective review by Krishnan et al.[12] suggests that dose escalation 
above a BED10 of 70Gy increases survival from 15 months to 17.8 months (p=0.03), whilst 
biophysical models suggest that this benefit can be further extended through dose escalation up to a 
BED10 of 100Gy [13].  Other studies have shown similar positive results when escalating above 
traditional thresholds [14,15]. In the majority of cases, dose escalation has been achieved using SBRT 
regimens (≤5 fractions) for targets smaller than 5cm in diameter [15] or located >1cm away from 
gastrointestinal (GI) OAR [12]. Dose escalation to sub-volumes of the targets (also known as 
simultaneous integrated boost or SIB) was also proposed for tumours without duodenal involvement 
[16,17]. However, any form of dose escalation is challenging for lesions in close proximity to OAR. 
For patients with unfavourable anatomy, moderate hypofractionation (e.g. 15 fractions) may facilitate 
dose escalation whilst maintaining OAR constraints. However, dose escalated moderate 
hypofractionation has not yet been fully evaluated in patients with OAR located less than 1cm away 
from the PTV. 
The aim of this study is to investigate the potential for dose escalation using hypofractionated 
radiotherapy for a group of LAPC patients with a varying degree of OAR proximity and evaluate if 
there is a dosimetric benefit of moderate hypofractionation in 15 fractions compared to 5 fractions in 
achieving a BED10≅100Gy.  
2. Materials and Methods 
2.1. Patients 
Following approval from the local institutional review board, CT planning scan images for ten 
consecutive LAPC patients treated with radical CRT (54Gy in 30 fractions) between May 2016 and 
November 2017 at our institution were re-contoured.  All patients had prospectively given consent for 
their anonymised data sets to be used for research purposes. The Planning Target Volume (PTV) was 
defined as the Gross Tumour Volume (GTV) plus a 5mm isotropic margin, assuming treatment 
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delivery in breath-hold using Active Breathing Coordinator (ABC)[18,19]. The duodenum, stomach, 
small bowel, large bowel, liver, kidneys, and spinal cord were identified as OAR and delineated.  
2.2. Fractionation and dose escalation  
Two fractionation regimens (5 and 15) were compared in this study. The base prescription dose was 
chosen to be equivalent to a BED10=54Gy, based on an SBRT prescription of 33Gy in 5 fractions [8]. 
In 15 fractions, the base prescription was 42.5Gy. The aim was to cover 95% of the PTV with the 
prescription dose for both fractionations with maximum dose to the PTV limited to 130% of the 
prescription dose. The OAR constraints (Table 1) were prioritized over target coverage. The OAR 
constraints for the two fractionations were taken from currently recruiting trial protocols [20,21]. In 
cases where 95% PTV coverage to the prescription dose could not be achieved, the highest achievable 
dose coverage whilst respecting the OAR constraints was reported.  
Table 1: OAR constraints for 5 and 15 fractions. 
Organ  5 fractions [20] 15 fractions [21] 
Duodenum V33Gy ≤ 0.5 cc V45Gy ≤ 0.5 cc 
Stomach V33Gy ≤ 0.5 cc V40Gy ≤ 0.5 cc 
Small bowel V33Gy ≤ 0.5 cc V45Gy ≤ 0.5 cc 
Large bowel V33Gy ≤ 0.5 cc V48Gy ≤ 0.5 cc 
Liver Dmean ≤ 20Gy and V15Gy ≤ 700cc Dmean ≤ 22 Gy  
Kidneys (combined)  Dmean ≤ 12 Gy  
Kidneys (each) Dmean ≤12 Gy and D67% ≤ 8 Gy V12Gy ≤10% * 
Spinal cord V25Gy < 0.5cc V35Gy ≤ 0.5cc 
* If solitary kidney or if Dmean >12Gy for one kidney 
 
Once this was achieved, dose escalation to a BED10≅100Gy was attempted. Dose prescriptions for the 
escalated plans were 50Gy in 5 fractions (BED10=100Gy) and 67.5Gy in 15 fractions (BED10=98Gy). 
The aim was to maximize the volume receiving the escalated dose whilst maintaining or increasing 
PTV coverage by the base dose (BED10=54Gy).  The maximum allowable dose to the PTV was 130% 
of the escalated dose. 
2.3. Treatment planning technique 
Volumetric Modulated Arc Treatment (VMAT) plans were designed according to our institutional 
standard for treatment on an Elekta linac with an Agility multi-leaf collimator (MLC) (Elekta AB, 
Stockholm, Sweden) with a single 6 MV Flattening-Filter Free (FFF) arc from 179° to 181° gantry 
rotation in Raystation 6.99 (RaySearch Laboratories, Stockholm, Sweden). The collimator rotation 
was set at 5° and the maximum MLC leaf speed was constrained at 0.6cm/deg to limit plan 
modulation and increase treatment efficiency. The delivery time was restricted to approximately 100s, 
such that treatment would be deliverable in 5-10 breath holds depending on patient compliance. 
2.4. Data analysis 
The achievable target coverage by the prescription dose was reported for all plans as well as the 
coverage by the base dose for the dose escalated plans. The Paddick conformity index [22] was 
calculated for all plans.  
The overlapping volume between the PTV and duodenum, stomach, small bowel or large bowel 
relative to the PTV volume was calculated as: 
𝑃𝑇𝑉𝑂𝐴𝑅 = 100
𝑣𝑜𝑙𝑢𝑚𝑒(𝑃𝑇𝑉∩𝑂𝐴𝑅)
𝑣𝑜𝑙𝑢𝑚𝑒(𝑃𝑇𝑉)
,  (eq. 2) 
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where 𝑂𝐴𝑅 =  (𝑑𝑢𝑜𝑑𝑒𝑛𝑢𝑚 ∪ 𝑠𝑡𝑜𝑚𝑎𝑐ℎ ∪  𝑠𝑚𝑎𝑙𝑙 𝑏𝑜𝑤𝑒𝑙 ∪  𝑙𝑎𝑟𝑔𝑒 𝑏𝑜𝑤𝑒𝑙). 
However, in some cases with little overlap, the OAR are abutting the target, therefore also limiting 
PTV coverage. In order to quantify this effect, the OAR proximity volume was calculated as the 
volume of OAR in the 1cm periphery of the PTV divided by the total PTV volume: 
𝑂𝐴𝑅𝑝𝑟𝑜𝑥 = 100
𝑣𝑜𝑙𝑢𝑚𝑒(𝑃𝑇𝑉𝑟𝑖𝑚∩𝑂𝐴𝑅)
𝑣𝑜𝑙𝑢𝑚𝑒(𝑃𝑇𝑉)
,  (eq. 3) 
where 𝑃𝑇𝑉𝑟𝑖𝑚 = (𝑃𝑇𝑉 + 1𝑐𝑚) ∖ 𝑃𝑇𝑉. 
The Pearson’s correlation coefficient was calculated between PTV volume, 𝑃𝑇𝑉𝑂𝐴𝑅 or 𝑂𝐴𝑅𝑝𝑟𝑜𝑥  and 
target coverage to investigate the effect of target size and OAR overlap or proximity on achievable 
coverage (significance level of 5%). 
3. Results 
Patients’ PTV volumes, limiting OAR, 𝑃𝑇𝑉𝑂𝐴𝑅 and 𝑂𝐴𝑅𝑝𝑟𝑜𝑥 volumes are listed in Table 2. 
Table 2: Target volume, dose limiting OAR and overlapping/abutting volumes 
Patient 
PTV  
volume [cc] 
GTV  
volume [cc] 
Closest OAR  
(volume overlap with 
PTV [cc])  
Duodenum, Bowel and Stomach: 
𝑃𝑇𝑉𝑂𝐴𝑅 [%]  
(eq. 1) 
𝑂𝐴𝑅𝑝𝑟𝑜𝑥  [%] 
(eq. 2) 
1 10.82 2.24 - 0.00 1.4 
2 52.96 19.07 Duodenum (5.97) 11.27 48.73 
3 33.41 10.41 Duodenum (2.02) 6.05 68.12 
4 52.27 19.87 Duodenum (8.7) 16.64 53.97 
5 92.51 43.44 Small bowel (0.56) 0.84 29.02 
   Stomach (0.22)   
6 196.73 103.57 Stomach (9.44) 7.04 43.35 
   Small bowel (1.73)   
   Large bowel (2.68)   
7 77.94 35.29 Duodenum (5.2) 6.67 33.64 
8 96.44 42.46 Duodenum (9.45) 10.07 56.25 
   Small bowel (0.17)   
9 57.52 23.69 Duodenum (5.64) 9.89 62.52 
10 222.81 134.01 Duodenum (7.77) 3.85 23.90 
   Large bowel (0.81)   
 
In 5 fractions, 95% PTV coverage by the base dose was achieved for patient 1 (PTVOAR=0%) with 
𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.85 (Figure 1) and for patient 5 (PTVOAR=0.84%) with 𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.9 (Figure 2, top). 
For the other patients, coverage was compromised in order to comply with OAR constraints 
(mean±SD PTV V33Gy=83±8%). PTV V33Gy was greater than 90% for Patients 7 and 10 (𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾 of 
0.81 and 0.77 respectively). In the dose escalated plans, 95% PTV coverage by the escalated dose was 
also achieved for patient 1 with 𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.85. For patient 5, PTV V33Gy was increased to 99%, 
however, V50Gy was limited to 79% (𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.77). For the other eight patients, PTV coverage by 
the base dose was slightly improved (Figure 1 top) (mean±SD PTV V33Gy=88±5%) and the mean±SD 
PTV coverage by the escalated dose was PTV V50Gy=40±19%. 
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Figure 1: Target coverage by the base (blue and red) and escalation (yellow) dose in 5 (top) or 15 
(bottom) fractions. (Blue bars indicate the base plans. Red and yellow bars indicate dose escalation 
plans. Darker bars indicate the GTV and lighter bars indicate the PTV). 
 
In 15 fractions, 95% PTV coverage by the base dose was achieved for nine out of ten patients (Figure 
1 bottom) with mean±SD 𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.89±0.03. For patient 6 who had significant overlap between 
the PTV and the stomach, PTV V42.5Gy was 86% with 𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.83. For the dose escalated plans, 
95% PTV coverage was achieved for patient 1 (𝐶𝐼𝑃𝐴𝐷𝐷𝐼𝐶𝐾=0.84). For the other patients, dose 
escalation to the PTV had to be compromised in order to comply with OAR constraints. The 
mean±SD PTV coverage by the escalated dose was PTV V67.5Gy = 42±17% and the PTV volume 
receiving the base dose was greater than 95% for all patients except patient 6 (PTV V42.5Gy=86%) 
(Figure 1 bottom).  
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Figure 2: Dose distribution for the escalated plan in 5 fractions (top) and 15 fractions (bottom) for 
patient 5. Target coverage is equivalent in the 2 fractionation regimen. 
The PTV volume receiving the escalated dose was greater for 5 fractions than 15 fractions for four 
patients, greater for 15 fractions than 5 fractions for four patients and equivalent for both fractionation 
for patient 1and 5 (Figure 3). Figure 4 shows the dose distributions for patient 2 which illustrates the 
better coverage by the base dose in 15 fractions (bottom) despite a better coverage by the escalated 
dose in 5 fractions (top). Plan delivery time was below 100s for all plans except one plan with a 
delivery time of 113s. 
 
Figure 3: Potential for dose escalation in 5 (blue bars, equal to yellow bars in fig 1 top) and 15 (red 
bars, equal to yellow bars in fig 1 bottom) fractions with a BED≅100Gy. 
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PTV volume, 𝑃𝑇𝑉𝑂𝐴𝑅 and 𝑂𝐴𝑅𝑝𝑟𝑜𝑥 are reported in Table 2. As expected, there was a strong, negative 
correlation between overlap metrics and PTV coverage by the base dose in 5 fractions and by the 
escalated dose in both fractionation regimens (correlation below -0.64 in all cases, p<0.05). The 
correlation between PTV volume and target coverage was low and non-significant for all 
fractionations. 
 
Figure 4: Dose distribution for the escalated dose plan in 5 fractions (top) and 15 fractions (bottom) 
for patient 2. PTV Coverage by the base dose (light green) is higher in 15 fractions (95%) than in 5 
fractions (86%). However, PTV coverage by the escalated dose (dark red) is higher in 5 fraction 
(51%) than in 15 fraction (32%). 
4. Discussion 
The benefit of a high BED for local control in LAPC has been previously demonstrated in tumours 
smaller than 5cm and/or more than 0.5cm away from GI OAR [7,12,15,23]. However, dose escalation 
is challenging when the anatomy is less favourable, especially using a 5 fraction SBRT approach. 
Moderate hypofractionation (e.g. 15 fractions) was investigated as a possible solution to this problem. 
In this study we compared the potential for dose escalation to a BED10≅100Gy in 5 or 15 fractions in 
an unselected group of LAPC patients representing a real-world population.   
The patients presented a range of PTVOAR and OARprox volumes leading to varying PTV coverage 
(Figure 1 and 2). In 5 fractions, 95% PTV coverage by the escalated dose was achievable for one 
patient and 95% coverage by the base dose was achieved for two patients with PTVOAR<1% indicating 
that patients with favourable anatomy may be treated to 50Gy in 5 fractions as described in other 
studies [7,12,15,23]. Two other patients had 90% PTV coverage by the base dose.  
In 15 fractions, 95% PTV coverage by 42.5Gy was feasible for all patients except one with overlap 
between the PTV and the stomach. The stomach had a more conservative dose constraints than the 
other OARs with no more than 0.5cc receiving 40Gy, whereas dose constraints to the other OARs was 
higher than the prescription dose of 42.5Gy.  
Our initial hypothesis was that dose escalation would be easier in 15 than in 5 fractions leading to 
larger sub-volumes of the PTV receiving the escalated dose in 15 fractions. This hypothesis was not 
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verified and treatment plans for 5 and 15 fractions showed equivalent performances over our cohort 
with a possible advantage of 15 fractions for larger tumours (patients 6, 8 and 10) although no 
significant correlation was found between target coverage and PTV volume. A 5-fraction regimen 
offers the advantage of a reduced overall treatment time and is less labour intensive in case of daily 
adaption. However, due to the risk of inter- and intrafractional anatomical changes, advanced adaptive 
technique should be used to ensure that OARs do not enter a high dose region. A 15-fraction regimen 
is more forgiving to interfractional errors, allows for concomitant chemotherapy and may be 
dosimetrically advantageous for large tumours. The longer overall treatment time may allow for 
response-based adaption. However, there is currently no prospective data for dose escalated 15 
fraction regimens, and therefore it remains to be seen whether toxicity rates including rates of 
lymphopenia and immunosuppression differ between the two regimens. 
Despite the similar potential for dose escalation, target coverage by the base dose was more easily 
achieved in 15 fractions than in 5 fractions (Figure 3 and 4). It is yet unknown whether a high dose to 
sub-volumes of the GTV is preferable to more complete coverage of the entire GTV by a lower dose. 
In the latter case, the required minimum sub-volume coverage and minimum boost dose should be 
investigated in prospective trials. 
The need to compromise the dose escalation to the PTV to comply with OAR constraints in dose 
escalated plans indicates that a heterogeneous dose distribution is most likely the best option to 
achieve a BED10≅100Gy for LAPC patients in hypofractionated regimens.  
Previous studies on heterogeneous dose prescription in pancreas SBRT aiming at boosting sub-
volumes of the PTV were limited to patients without duodenal involvement [16,17]. Wo et al. 
investigated the effect of dose painting to deliver a higher dose (BED10=71.2Gy) in 28 fractions to 
regions of vessels involvement with the aim to convert unresectable and borderline resectable cases to 
resectable [16]. They found dose painting to be feasible and well tolerated and 37% of the patients 
were able to proceed to resection. Shaib et al investigated the use of a simultaneous integrated boost 
(SIB) to the posterior margin (PM) of borderline resectable patients [17]. The PM dose ranged from 
36 to 45Gy in 3 fractions (BED10 from 79.2 to 112.5Gy) whilst the dose to the PTV was either 30 or 
36Gy (BED10=60 or 79.2Gy). Dose limiting toxicity was not reached and eight of thirteen patients had 
R0 resection after SBRT.  
Gkika et al. used a de-escalation approach using simultaneous integrated protection (SIP). This 
involved reduced dose to PTV sub-volumes overlapping with OAR protection volumes [24]. They 
observed a favourable toxicity profile without compromise in tumour control. 
In the present study, heterogeneous dose distributions were not prescribed but were accepted as a 
result of mandatory OAR constraints. Henke et al. used a similar strategy in 5 fractions [25,26]. They 
report a mean 70.7% PTV coverage by the 95% isodose line (47.5Gy) for non-liver abdominal cases 
in initial plans and suggest a potential improvement in a less hypofractionated regimen [26]. Note also 
that PTV coverage by the base dose was higher in all dose escalated plans compared to the 
corresponding base dose plans (both in 5 and 15 fractions). A higher maximum dose constraint (130% 
of the escalated dose as compared to 130% of the base dose) results in a more heterogeneous dose 
within the PTV and allows improved coverage by the base dose. 
It should be noted that the base dose of BED10=54Gy was chosen from previous multi-institutional 
SBRT series [8]. Whilst being slightly lower than conventional fractionation with 54Gy in 30 
fractions (BED10=64Gy), SBRT has been linked to better outcomes than conventional treatments [11]. 
Possible explanations for this include the radiobiological advantage associated with reduced overall 
treatment time, as well as the alternative mechanisms of cell kill associated with SBRT such as 
vascular and immune mediated effects [27]. Shortening the treatment period to 1-3 weeks offers a 
more convenient schedule to patients, which is particularly relevant given the generally poor 
prognosis of this population. 
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A limitation of this study is the equivalence of OAR dose constraints in the two fractionation 
regimens. The constraints are not BED equivalent (/β =3 for GI OAR) but were based on currently 
recruiting trial protocols [20,21]. It is acknowledged that there is some uncertainty over the true 
tolerances of GI OAR and the validity of the linear-quadratic model with high dose per fraction 
treatments. GI OAR tolerances may be further refined in the future, with the aid of prospectively 
collected toxicity data from current clinical trials [23,28]. The 15 fraction constraints were taken from 
a currently recruiting study evaluating dose escalation in locally advanced biliary tract cancers [21]. 
Whilst not a pancreas specific protocol, these were pragmatically chosen to reflect the most up-do-
date 15 fraction constraints for abdominal hypofractionation. They are in-line with published 
retrospective series describing clinical outcomes using 15 fraction dose escalated series with 
acceptable toxicity [12,29].  
Other limitations of this study include the choice of 5mm isotropic PTV margin. This was deemed 
sufficient in previous studies of residual liver motion under ABC [18,19] or pancreatic motion during 
gating [17,30]. Using online MR-guidance, gated pancreatic RT with PTV margins of 3mm has been 
demonstrated previously [25] and also offers the potential for daily recontouring and replanning in an 
integrated workflow. A 3mm margin would allow improved target coverage in general but requires 
strict motion management under image guidance. 
In addition to target motion, OAR motion is an important consideration. Planning at Risk volumes 
(PRV) are sometimes used to ensure OAR protection [7] but were not used in this study. It is 
acknowledged that a PRV approach may be preferred when dose escalating to OAR tolerance unless 
daily adaption is available. This would most likely reduce the achievable coverage, especially by the 
escalated dose. 
Finally, the achievable target coverage by the base dose in 5 fractions and the coverage by the 
escalated dose in 5 and 15 fractions were all significantly correlated with the percentage of PTV 
volume overlapping with OAR and the proximity of OAR to the PTV. Interestingly, PTV volume did 
not show a correlation with target coverage in either fractionation schedule. These correlations are 
important as overlap and proximity may alter during treatment due to interfraction OAR motion. 
These changes can be capitalised upon using daily adaptive replanning to increase coverage by the 
prescription dose on days with favourable anatomy [25]. Using a base dose plan established prior to 
treatment as a starting point, dose escalation can be optimized online based on the anatomy of the day. 
Conclusions 
This study showed that dose escalation to sub-volumes of the PTV is dosimetrically feasible in 5 or 15 
fractions for an unselected LAPC population. The proposed strategy to cover the PTV by a base dose 
with BED10=54Gy and maximize coverage by a BED10≅100Gy would be particularly well suited for 
daily adaptive workflow where dose escalation can be optimized depending on the anatomy of the 
day. 
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Maximum 85 characters including spaces per bullet point 
 The dose for hypofractionated RT for LAPC is limited by the proximity of OAR 
 Uniform target coverage by a BED of 54Gy is easier in 15 than in 5 fractions 
 But the dose escalation potential to a BED of 100Gy is similar in 5 or 15 fractions 
 Larger tumour sub-volumes may receive a high dose on days with favourable anatomy 
 
 
